GlassScriptPhysician profile
Ian B Deroock
NPI 1114900479
$18,329.66
in general payments reported to CMS, 2019-2025
77 companies · $2,887 in 2025
The $2,887 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $1,508 · 2021: $3,225 · 2022: $3,213 · 2023: $2,567 · 2024: $3,331 · 2025: $2,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,994 · Consulting Fee: $525 · Long Term Medical Supply Or Device Loan: $167 · Education: $99.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,994.06 |
| Consulting Fee | $525.00 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $99.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,197.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,502.81 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Janssen Biotech, INC. | $1,223.78 | 2019-2025 | Tecvayli, Rybrevant, Talvey |
| Pfizer INC. | $1,047.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $716.60 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $694.18 | 2019-2025 | Reblozyl, Pomalyst |
| Eisai INC. | $596.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $569.16 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Seagen INC. | $503.48 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Daiichi Sankyo INC. | $493.06 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Rigel Pharmaceuticals, INC. | $455.10 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genzyme Corporation | $450.82 | 2019-2025 | |
| Amgen INC. | $448.95 | 2019-2023 | Lumakras |
| Abbvie INC. | $418.70 | 2020-2025 | Venclexta |
| Glaxosmithkline, LLC. | $404.24 | 2020-2025 | Jemperli, Zejula, Ojjaara |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Deroock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.